Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | CD274 positive |
Therapy | Capecitabine + Cisplatin + Pembrolizumab |
Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Capecitabine + Cisplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin), is included in guidelines as preferred first-line therapy for patients with gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10), and without ERBB2 (HER2) overexpression (category 1), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <10) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |